Scarica l'app Stockscreener
33.48
0.37%
0.11
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Long Term Trading Analysis for (XENE) - news.stocktradersdaily.com
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
Xenon Pharmaceuticals price target raised to $57 from $55 at RBC Capital - Investing.com Canada
RBC Raises Price Target on Xenon Pharmaceuticals to $57 From $55, Keeps Outperform, Speculative Risk - MarketScreener
Cantor Fitzgerald Estimates XENE FY2026 Earnings - MarketBeat
Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Xenon Pharmaceuticals at Goldman Sachs Conference: Strategic Clinical Advances By Investing.com - Investing.com Canada
Transcript : Xenon Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 03 - MarketScreener
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Squarepoint Ops LLC - Defense World
xenon pharmaceuticals reports shareholder voting results By Investing.com - Investing.com South Africa
xenon pharmaceuticals reports shareholder voting results - Investing.com
(XENE) Trading Advice - news.stocktradersdaily.com
Xenon to Present at the Goldman Sachs 46th Annual Global Healthc - GuruFocus
Xenon Pharmaceuticals to Present at Global Healthcare Conference - TipRanks
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | XENE Stock News - GuruFocus
Xenon CEO to Update Investors on Breakthrough Epilepsy Drug at Goldman Sachs Healthcare Conference - Stock Titan
Stock Traders Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Analyzing Xenon Pharmaceuticals (NASDAQ:XENE) and Inhibitor Therapeutics (OTCMKTS:INTI) - Defense World
Xenon Pharmaceuticals Announces Equity Inducement Grants for New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Lis - GuruFocus
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Awards $1.5M in Stock Options to 7 New Hires Under Nasdaq Rule - Stock Titan
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE - Defense World
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - Defense World
Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Xenon Pharmaceuticals at RBC Capital Markets: Strategic Insights on Ezetucalmer - Investing.com India
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Xenon Pharmaceuticals’ SWOT analysis: neurological drug stock faces pivotal year - Investing.com India
Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World
Leerink Partnrs Has Bullish Forecast for XENE Q2 Earnings - Defense World
XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
What is William Blair’s Estimate for XENE FY2025 Earnings? - Defense World
Wedbush Equities Analysts Cut Earnings Estimates for XENE - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Evercore ISI - Defense World
HC Wainwright Issues Optimistic Outlook for XENE Earnings - Defense World
How To Trade (XENE) - news.stocktradersdaily.com
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Chardan Capital Reiterates “Buy” Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Needham & Company LLC Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00 - Defense World
Wells Fargo & Company Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Upgraded by StockNews.com - Defense World
Evercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Xenon signals Phase 3 epilepsy readout in early 2026 with expanded pipeline advancements - MSN
Xenon Pharmaceuticals to Present at 2025 RBC Healthcare Conference - TipRanks
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Ra - GuruFocus
XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Rating | XENE Stock News - GuruFocus
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday - Insider Monkey
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call Transcript - Insider Monkey
XENE: Wells Fargo Adjusts Price Target for Xenon Pharmaceuticals - GuruFocus
Xenon Pharmaceuticals (XENE) Price Target Adjusted by Analyst | - GuruFocus
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):